Introduction
2-Chloro-2′-deoxyadenosine (CdA) is an analogue of deoxyadenosine with major antitumor activity in indolent lymphoid malignancies including chronic lymphocytic leukemia (CLL). 1 CdA is resistant to adenosine deaminase, an enzyme which plays an important role in the degradation of purine nucleosides. Intracellularly, CdA is phosphorylated initially by deoxycytidine kinase into its 5′-monophosphate, CdAMP, and thereafter converted successively into CdADP and CdATP. The latter triphosphate is considered the active metabolite of CdA, and has been shown to interfere with DNA synthesis through inhibition of DNA polymerase ␤ and ribonucleotide reductase.
Since the latter enzymes are also involved in DNA repair, it is conceivable that CdA may influence this process. Accordingly, CdA has been shown to block DNA repair synthesis in X-irradiated lymphocytes, a property which has been explored more extensively with fludarabine, another analogue of deoxyadenosine, which inhibits DNA repair synthesis elicited by alkylating agents or UV-irradiation. [3] [4] [5] Interference of CdA with DNA repair raises the possibility that CdA might produce synergistic antitumor effects when combined with agents that evoke a DNA repair response. Cyclophosphamide (CP), a bifunctional DNA alkylating agent belonging to the nitrogen mustard family, is one of the most active compounds in this respect, in addition to being one of the most widely used anticancer agents and, moreover, active in CLL. 6 Cross-linking of DNA strands is a major biochemical action accounting for cytotoxicity of CP and CP derivatives. 7, 8 To evaluate the potential benefits of the combination of CP and CdA in B-CLL, the modulator effect of CdA on the cytotoxicity of CP was examined in vitro. In these studies, CP was replaced by 4-hydroxycyclophosphamide (4HC), its active metabolite produced by microsomal oxidation in the liver, and by mafosfamide (MAF), which yields 4HC by rapid hydrolysis in aqueous conditions. 7 The results of these experiments provided a rationale for the clinical association of CdA and CP, a regimen barely investigated hitherto.
9,10

Patients and methods
Patients
Samples were freshly obtained from 25 patients with B-CLL. All patients fulfilled the National Cancer Institute criteria for the diagnosis of B-CLL. Clinical staging was based on the system described by Binet. 11 Patients were at all stages of disease and free of any anticancer treatment for at least 3 months. Binet staging ranged from A to C. Fourteen patients had never received chemotherapy, while 11 had been treated with various regimens including chlorambucil (CLB) (n = 8), a purine analogue as single agent (CdA: n = 6; fludarabine: n = 1), CHOP (CP, doxorubicin, vincristine, prednisone: n = 1) and high-dose corticosteroids (n = 1). The median number of prior regimens was two (range 1-5). All the patients who had been pretreated with a purine analogue were in relapse or progression. Eleven patients (eight pretreated, three untreated) had a lymphocyte count doubling time of less than 12 months.
Isolation of lymphocytes and cell culture
Freshly obtained peripheral blood from B-CLL patients was fractionated by Ficoll-Paque sedimentation. Mononuclear cells were washed with cold PBS and resuspended in RPMI 1640 supplemented with 10% FBS and 1% penicillin (10000 U/ml)-streptomycin (10 mg/ml). Cells were counted, diluted to indicated concentration in RPMI, and incubated at 37°C in 5% CO 2 .
Drug exposure, analysis of cytotoxicity and drug interaction
B-CLL cells, resuspended at a concentration of 1.5 × 10 6 /ml, were exposed to CdA or CP derivatives for 24 h. When CdA and CP derivatives were combined, CdA was added 2 h before CP derivatives. 4HC and MAF were freshly dissolved in sterile water prior to each experiment. Stock solution of CdA was prepared in ETOH/NaCl 0.9% (v/v). After drug exposure, 7 ml of cell suspension were washed with RPMI, resuspended in 200 l RPMI and seeded in 96-well microtiter plates. Controls and each drug concentration were set up in triplicate. Viability of cells after drug treatment was measured 72 h after washing, using the MTT assay. 12 The optical density (OD) of each well was measured at 540 nm with a Multiwell Scanning Spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). Leukemic cell survival (LCS) was calculated by the equation: (mean OD of treated well/mean OD of control wells) × 100%. Interaction between drugs, ie synergism, additivity or antagonism, was defined according to the multiplicative and maximum models as used by Kaspers et al. 12 In the multiplicative model, the expected effect of a drug combination is the product of the effect of each single drug. In the maximum model, the expected effect of a combination is equal to that of the most active single drug. These models were combined to establish the interactions between drugs:
, where D max is the effect of the most active single drug; and antagonism if observed LCS (drug A + drug B) Ͼ LCS (D max ). The LC 50 was defined as the drug concentration that results in 50% LCS, and was determined graphically as the point where the doseresponse curve crosses the 50% LCS point.
Annexin V binding
Apoptotic cells, with exposure of phosphatidylserine on the outer leaflet, and necrotic cells were quantified by flow cytometry after annexin V and propidium iodine (PI) double labeling. 13 Briefly, after 24 h incubation with or without drugs as indicated, cells were washed twice in cold PBS and then resuspended at a concentration of 1 × 10 6 /ml in Hepes buffered saline solution supplemented with 25 mM CaCl 2 . One hundred microliters of the cells were incubated for 15 min at room temperature in the presence of fluorescein-conjugated annexin V (10 l of 10 g/ml stock) and PI (10 l of 50 g/ml stock). 
Cellular morphology
At the indicated times, 5 × 10 5 cells were centrifuged on to glass slides, fixed with methanol, and stained with May-Grü nwald-Giemsa. Cell morphology was examined by light microscopy using a BH2 microscope (Olympus, Tokyo, Japan). Apoptotic morphology was determined by standard criteria, including chromatin condensation, nuclear margination and cellular shrinkage. Necrotic cells were defined by the following characteristics: cytoplasmic vacuolization, cell and nuclear swelling, rupture of nuclear and plasma membranes, appearance as faintly stained cells with nuclear ghosts. At least 400 cells in a minimum of three fields of view were counted from duplicate slides for each sample by different experienced observers. 14 UV detection of nucleotides was performed at 254 nm. Fractions corresponding to 1 min of elution were collected and their radioactivity was determined by scintillation counting. Radioactivity incorporated in the acid-insoluble pellet was measured after washing of the pellet followed by digestion with soluene.
Quantitation of adenylic nucleotides and intracellular metabolites of [8-
DNA fragmentation analysis
High molecular weight DNA fragmentation (HMWF) was analyzed by pulsed field gel electrophoresis as previously described. 15 Briefly, after drug treatment, 10 5 B-CLL cells were embedded in 0.6% agarose plugs. After a 24-h incubation in lysis buffer containing 1% Sarkosyl and proteinase K, the plugs were loaded into 1% agarose gels, and DNA was separated with a CHEF-DRII system (Bio-Rad Laboratories, Richmond, CA, USA). Gels were stained with ethidium bromide and photographed.
Statistical analysis
Differences in LCS between control and treated cells, or between intracellular metabolites of H]CdA accumulated with or without MAF, were analyzed for statistical significance by the two-tailed Student's t-test for paired or unpaired samples, at a level of significance of P р 0.05. The same method was applied to compare LCS from untreated and previously treated patients. All mean values were calculated from experiments performed in different patients. H]CdA B-CLL cells were incubated with 0.5 M [8- 3 H]CdA. The kinetics of accumulation of CdAMP, CdADP, and CdATP are shown in Figure 1 . Intracellular phosphorylated metabolites of CdA were already detectable 15 min after the start of the incubation. Accumulation of CdAMP was predominant, followed by that of CdATP, whereas that of CdADP was negligible. The intracellular levels of CdATP (pmoles/10 6 cells, mean ± s.e.m.) reached 0.19 ± 0.05 after a 2-h, and 0.20 ± 0.07 after a 24-h incubation with CdA. Compared to the accumulation of its phosphorylated metabolites, incorporation of CdA into nucleic acids was limited: it reached 0.004 ± 0.001 and 0.045 ± 0.012 pmoles/10 6 cells after 2 and 24 h, respectively. This indicated that a 2-h preincubation with CdA before CP derivative addition was long enough to allow sufficient formation of CdATP, the putative active metabolite of CdA.
Results
Time course of CdA nucleotide concentrations in B-CLL cells incubated with
In vitro cytotoxicity in B-CLL cells of CdA, MAF and 4HC
As shown in Figure 2 Combination experiments were performed with two concentrations of CdA, 0.05 and 0.1 M, and with concentrations of MAF and 4HC derived from the dose-response curves depicted in Figure 2 . The B-CLL lymphocytes were incubated in the presence of CP derivatives during 22 h, after a 2-h preincubation with or without CdA. As shown in Figure 3 , the dose-response curve to MAF was markedly shifted to the left upon preincubation with CdA. In the presence of 0.05 (Figure 3a) or 0.1 M (Figure 3b ) CdA, the LC 50 of MAF was reduced by a factor of 8 and 23, respectively. Potentiation of MAF cytotoxicity by 0.05 M CdA was obtained despite a low cytotoxicity of CdA as single agent at this concentration (median LCS: 76%, range 43-102% for n = 13). The greatest potentiating effect of CdA was recorded at 2 M MAF. The cytotoxicity of 4HC was similarly increased by preincubation of the cells with CdA. LCS (%, mean ± s.e.m. for n = 4), which after incubation with 0.5 and 2 M of 4HC alone was 89 ± 5 and 69 ± 9, respectively, decreased to 46 ± 10 and 24 ± 10, respectively, upon preincubation of the cells with 0.05 M CdA.
In order to determine the importance of drug scheduling, cells were treated either with 2-h CdA followed by 18-h MAF, or with 2-h MAF followed by 18-h CdA. Although potentiation occurred in all conditions, the sequence of CdA followed by MAF was slightly, although non-significantly, more active (data not shown).
Effect of CdA on the toxicity of MAF was also analyzed using annexin V/PI staining and two-parameter flow cytometer analysis. Cytotoxicity of increasing concentrations of MAF was augmented in the presence of 0.1 M CdA. The percentage (mean ± s.e.m., for n = 4) of annexin V + (and either PI + or PI − ) cells after MAF 0.2 M, 2 M, and 5 M was 45 ± 7, 48 ± 7, and 63 ± 8 without CdA, and 63 ± 8, 77 ± 6, and 83 ± 5 in the presence of 0.1 M CdA, respectively. Potentiation of MAF toxicity by CdA was found to be highly significant at all the concentrations of MAF tested (P р 0.02). Mean percentage (± s.e.m., for n = 4) of annexin V + cells in samples incubated during 24 h without drugs or with CdA 0.1 M alone was 37 ± 2 and 58 ± 7, respectively.
Characterization of in vitro drug interactions
To differentiate between synergism, additivity and antagonism, LCS were analyzed according to the multiplicative and maximum models as detailed in the Methods section. Figure 4 shows the comparison between the expected LCS values, as predicted by both the multiplicative and the maximum model, and the observed LCS values for each drug combination. The multiplicative model identifies synergistic interactions (when the observed LCS (drug A + drug B) is lower than the expected LCS (drug A + drug B)), whereas the maximum model enables identification of antagonism (when the observed LCS (drug A + drug B) is higher than the LCS of the most active single drug). Analysis of 24 experiments at up to five different concen- trations, resulting in 43 individual comparisons between observed and expected LCS, showed synergistic interaction in 72%, additivity in 19%, and antagonism in 9% of the samples treated with CdA and MAF. Antagonism between CdA and MAF, which occurred most frequently at the lowest concentration of MAF, was found exclusively in previously treated patients (n = 4). When LCS observed for the combination of CdA and MAF was compared to LCS for the most active single drug in each individual experiment, a highly significant difference was found (P Ͻ 0.01). This shows that, overall, the drug combination was significantly more toxic than the most active single drug. The combination of CdA and 4HC was tested in four different samples, at up to four different concentrations, which resulted in eight comparisons between the expected and observed LCS values. Synergism between CdA and 4HC was found in 100% of the samples in which this combination was tested (not illustrated). The observed LCS for the combination of CdA and 4HC was significantly lower than the LCS of the most active single drug when these values were compared in each individual experiment (P Ͻ 0.01).
Accordingly, when the toxicity of MAF ± CdA, as assessed by annexin V/PI double staining, was analyzed for drug interaction, the majority (11/12) of the pairs tested showed synergistic interaction, and 1/12 showed additivity.
Characteristics of cell death following incubation with drugs
Cell death induced by CdA was associated with morphological changes of apoptosis such as chromatin condensation and cell shrinkage, in comparison with control cells (Figure 5a 
Effect of MAF on the metabolism of [8-3 H]CdA
To detect an influence of MAF on the phosphorylation of CdA, B-CLL cells were incubated in the presence of 0.5 M [8- Cellular ATP concentrations (pmoles/10 6 cells, mean ± s.e.m. for n = 3) tended to be lower in samples treated with CdA and MAF (0.13 ± 0.05) than in samples treated with CdA alone (0.22 ± 0.08, P = 0.12).
Correlations between sensitivity of B-CLL cells to CdA ± MAF and clinical status
B-CLL cells from different patients showed a wide range of sensitivities to CdA, to MAF and to 4HC. Sensitivity varied up to 2.3-fold for CdA 0.05 M and up to 2.8-fold for CdA 0.1 M. Sensitivity to MAF 0.2, 2 and 5 M varied up to 2.1-, 4.6-and 46.7-fold, respectively. LCS (%, mean ± s.e.m.) after 2 M MAF was significantly lower (P = 0.02) in previously untreated patients (55 ± 8 for n = 13) than in pretreated patients (78 ± 6 for n = 9). After 5 M MAF, LCS in samples from chemotherapy naive patients (10 ± 2 for n = 7) was significantly lower (P = 0.01) than in pretreated patients (43 ± 10 for n = 8). Similarly, cells from untreated patients were significantly more sensitive to CdA 0.05 M (P Ͻ 0.05) than cells from pretreated patients. Although the combination of CdA 0.5 M with MAF 0.2 M caused significantly (P Ͻ 0.01) more cytotoxicity in untreated patients than in pretreated patients, no differences in LCS were found according to the clinical status with the other combinations of CdA and MAF. 
Discussion
Purine analogues such as CdA and fludarabine demonstrate marked antitumor activity in terms of frequency and duration of responses in B-CLL. 1, 16 However, despite these results, follow-up of CLL patients treated with CdA or fludarabine in first line does not clearly show a survival advantage over conventional therapies of CLL. 2, 17, 18 Theoretically, a possible way to achieve better results in CLL is to combine purine analogues with other agents. Indeed, CdA has been shown to interfere with various enzymes associated with DNA repair. 2, 19 DNA repair inhibition by CdA may hence increase the accumulation and slow the removal of DNA damage induced by drugs such as alkylating agents, leading to enhanced cytotoxicity of the latter. This strategy could also offer an opportunity to circumvent cellular resistance due to enhanced DNA repair capability, a phenomenon which may partially play a role in the resistance to alkylating agents in CLL. [20] [21] [22] [23] In the present report, we have investigated the effect of the combination of CdA with CP derivatives on B-CLL cells in vitro. A 2-h preincubation with CdA before MAF or 4HC addition was judged to be adequate given the rapid intracellular accumulation of CdATP. In the majority of samples tested, we observed synergistic or additive cytotoxicity between CdA and CP derivatives. Antagonism between CdA and MAF, although rare, occurred more frequently in pretreated/resistant patients and at the lowest concentration of MAF. However, by raising the concentration of MAF, antagonism with CdA was no longer seen in these patients and all had enhancement of the cellular toxicity of MAF by CdA. In two patients relapsing after CdA, and clinically refractory to CLB, who displayed in vitro resistance to MAF, CdA increased the toxicity of MAF. These two patients further proved to be clinically sensitive to the combination of CdA with CP. These data suggest that, by adding CdA, B-CLL cells isolated from patients pretreated and/or refractory to alkylating agents were brought into a more sensitive range at the in vitro level and that this favorable interaction is susceptible to hold true in vivo. Although in vitro studies are not always translatable to the clinic, the concentrations of CdA and 4HC chosen were in the range of what can be achieved in the plasma of patients treated with CdA or CP. 24, 25 Furthermore, our in vitro schedule was relevant to the clinical situation where rapid intracellular accumulation of CdA nucleotides has been shown after 2-h i.v. or oral CdA. 24 A similar level of synergy was observed between CdA and 4HC, although studies with the latter were more limited.
The mechanisms underlying the synergism between CdA and CP derivatives remain speculative. This interaction was due neither to an enhancement in the phosphorylation of CdA to its active metabolites by MAF, nor to a greater incorporation of CdA into nucleic acids in the presence of MAF. In keeping with previous reports, the morphological and biochemical characteristics of cell death by apoptosis were observed in samples treated with CdA and/or MAF. 26, 27 The morphological data also suggests that the gain in cell death achieved by adding CdA to MAF may be partially due to an increased incidence of necrosis in addition to cell death by apoptosis. Compared to the cells treated with CdA alone, the decline in cellular ATP in the cells treated with CdA and MAF accords with a greater cellular dysfunction with the latter combination. Although not demonstrated in this study, the synergism between CdA and CP derivatives may proceed from inhibition of DNA repair by CdA, which thereby enhances the toxicity of MAF or 4HC. CdA has indeed been shown to inhibit the polymerization step of DNA repair in X-irradiated normal lymphocytes, and to interfere with the repair of DNA double-strand breaks in X-irradiated Chinese hamster V79 cells, thereby enhancing the lethal effects of X-rays. 3, 28 Furthermore, therapeutic synergy between CdA and CP was observed in mice bearing leukemia P388 and L1210. 29 Synergistic antitumor activity was also shown in CLL cells between CLB and CdA. 30 However, this synergy was only observed if the cells were treated with CLB prior to CdA and no effect of CdA on the repair of CLB-induced cross-links was shown. This last observation, as mentioned by the authors, could be explained by the higher concentrations of CLB required to detect DNA cross-links in the alkaline elution assay, as compared to the cytotoxicity assay. The concentrations of CdA allowing synergy with CLB were also higher (10-fold) than in our study and superior to those observed in the plasma of patients receiving the standard dose of CdA. Other purine analogues, including fludarabine and deoxycoformycin, have been clearly shown to restrain DNA repair elicited by UVirradiation, X-irradiation, or DNA cross-linking.
Several clinical combination regimens including fludarabine or CdA and a DNA damaging agent have been reported in B-CLL. Although proven efficacious, administration of adequate doses of CdA or fludarabine in association with CLB has been limited by the occurrence of protracted pancytopenia following these combinations. 17, 33, 34, 35 Yet, administration of oral CdA with CP in patients with Waldenströ m's disease was reported to be active and safe. 9 The combination of CdA, CP and prednisone was feasible and active in previously untreated patients with CLL or low grade NHL. 10 That of fludarabine and CP was shown to be the most active salvage regimen in patients in relapse after, or refractory to, fludarabine as single agent. Other combination therapies including purine analogues are active in CLL, although there is no clear evidence yet for a superiority over fludarabine or CdA in this disease. 2, 16 The assumption that CP, compared to CLB, has a favorable profile of clinical toxicity in combination with purine analogues, together with the results of this study, led us to design an ongoing phase I trial of CdA in combination with CP in patients with CLL. Further studies are also in progress to determine whether in vitro sensitivity to CdA and MAF may predict clinical response to this combination, and, hence, help to tailor chemotherapy on a more individual basis.
In conclusion, the results of the present study, demonstrating synergistic cytotoxicity in vitro between CdA and CP derivatives, further support the rationale of combining purine analogues with DNA-damaging agents in the clinical management of patients with B-CLL. As suggested by our data, this strategy should not be limited to previously untreated or sensitive patients.
